

Retraction of: PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors

Retraction of: Shayesteh R Ferdosi, Brett Taylor, Matthew Lee, Nanyun Tang, Sen Peng, Rita Bybee, George Reid, Lauren Hartman, Krystine Garcia-Mansfield, Ritin Sharma, Patrick Pirrotte, Jianhui Ma, Alison D Parisian, Frank Furnari, Harshil D Dhruv, Michael E Berens, PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors, *Neuro-Oncology*, Volume 24, Issue 11, November 2022, Pages 1857–1868, <https://doi.org/10.1093/neuonc/noac067>

The authors of this article wish to note that due to an error in the combination index calculation, their report of synergy (Figure 6C and 6D) from the combinations of pevonedistat plus etoposide and pevonedistat plus doxorubicin in M059K and SNU1105 glioma cells was false. TOP2A inhibitors

combined with MLN4924 are not synergistic in PTENnull cells.

The title's declaration that TOP2A inhibition overcomes resistance to MLN4924 is erroneous.

Therefore, although other findings in the publication have proven to be accurate and reproducible, due to this unfortunate error the authors have unanimously requested that the article be fully retracted. The authors apologize to the readers and reviewers of *Neuro-Oncology*.

As a consequence of this article's retraction, the corresponding Editorial Commentary is also retracted by the Journal (Goenka A, Cheng SY, Targeting neddylation in cancer, *Neuro-Oncology* 2022 24(11); 1869–1870. <https://doi.org/10.1093/neuonc/noac159>